ERBB2 and triple-negative breast carcinoma: For the HER2-positive subtype and triple-negative breast cancer, recent approvals have expanded options with drugs such as tucatinib [67], trastuzumab deruxtecan [68], pembrolizumab [69], and sacituzumab govitecan [70].